Sk Biopharmaceuticals Co Ltd
SK Biopharmaceuticals Co., Ltd., a pharmaceutical company, engages in the research, development, and commercialization of drugs for the treatment of central nervous system disorders. The company offers Cenobamate, an anti-seizure medication for the treatment of epilepsy and Solriamfetol medication. It develops Carisbamate that is in Phase 3 trials to treat lennox-gastaut syndrome; Relenopride, wh… Read more
Sk Biopharmaceuticals Co Ltd - Asset Resilience Ratio
Sk Biopharmaceuticals Co Ltd (326030) has an Asset Resilience Ratio of 0.16% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2016–2024)
This chart shows how Sk Biopharmaceuticals Co Ltd's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Sk Biopharmaceuticals Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩1.67 Billion | 0.16% |
| Total Liquid Assets | ₩1.67 Billion | 0.16% |
Asset Resilience Insights
- Limited Liquidity: Sk Biopharmaceuticals Co Ltd maintains only 0.16% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Sk Biopharmaceuticals Co Ltd Industry Peers by Asset Resilience Ratio
Compare Sk Biopharmaceuticals Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
argenx SE
OTCGREY:ARGNF |
Biotechnology | 25.67% |
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Exicure Inc
NASDAQ:XCUR |
Biotechnology | 0.00% |
|
Shenzhen CAU Technology Co Ltd
SHE:000004 |
Biotechnology | 6.20% |
|
Nanhua Bio Medicine Co Ltd
SHE:000504 |
Biotechnology | 11.93% |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403 |
Biotechnology | 6.88% |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518 |
Biotechnology | 0.03% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
Annual Asset Resilience Ratio for Sk Biopharmaceuticals Co Ltd (2016–2024)
The table below shows the annual Asset Resilience Ratio data for Sk Biopharmaceuticals Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 0.16% | ₩1.68 Billion | ₩1.04 Trillion | -0.03pp |
| 2023-12-31 | 0.20% | ₩1.42 Billion | ₩723.17 Billion | -30.12pp |
| 2022-12-31 | 30.32% | ₩201.39 Billion | ₩664.24 Billion | +13.48pp |
| 2021-12-31 | 16.84% | ₩108.42 Billion | ₩643.65 Billion | -48.86pp |
| 2020-12-31 | 65.70% | ₩328.66 Billion | ₩500.24 Billion | +43.24pp |
| 2019-12-31 | 22.46% | ₩31.23 Billion | ₩139.07 Billion | +20.12pp |
| 2018-12-31 | 2.34% | ₩2.24 Billion | ₩95.54 Billion | -37.39pp |
| 2017-12-31 | 39.73% | ₩39.08 Billion | ₩98.37 Billion | -27.41pp |
| 2016-12-31 | 67.14% | ₩130.18 Billion | ₩193.89 Billion | -- |